ATE465149T1 - Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen - Google Patents
Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänenInfo
- Publication number
- ATE465149T1 ATE465149T1 AT97907937T AT97907937T ATE465149T1 AT E465149 T1 ATE465149 T1 AT E465149T1 AT 97907937 T AT97907937 T AT 97907937T AT 97907937 T AT97907937 T AT 97907937T AT E465149 T1 ATE465149 T1 AT E465149T1
- Authority
- AT
- Austria
- Prior art keywords
- immunophilin
- chimeric proteins
- rapamycin derivatives
- derived domain
- multimerizing agents
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 102000000521 Immunophilins Human genes 0.000 abstract 3
- 108010016648 Immunophilins Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1243296P | 1996-02-28 | 1996-02-28 | |
| US2486196P | 1996-08-28 | 1996-08-28 | |
| US3303596P | 1996-12-10 | 1996-12-10 | |
| PCT/US1997/003137 WO1997031898A1 (en) | 1996-02-28 | 1997-02-28 | Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465149T1 true ATE465149T1 (de) | 2010-05-15 |
Family
ID=27359637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97907937T ATE465149T1 (de) | 1996-02-28 | 1997-02-28 | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0888303B1 (de) |
| JP (2) | JP4936345B2 (de) |
| AT (1) | ATE465149T1 (de) |
| AU (2) | AU731826B2 (de) |
| CA (1) | CA2244363C (de) |
| DE (1) | DE69739853D1 (de) |
| WO (2) | WO1997031898A1 (de) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2244363C (en) * | 1996-02-28 | 2006-11-14 | Ariad Gene Therapeutics, Inc. | Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains |
| US5945441A (en) * | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
| US20010049381A1 (en) | 1997-06-04 | 2001-12-06 | Gpl Nil Holdings, Inc., | Pyrrolidine derivative hair growth compositions and uses |
| US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| EP1053241A1 (de) * | 1998-02-13 | 2000-11-22 | President And Fellows Of Harvard College | Dimerisierung verbindungen, ihre herstellung und verwendung |
| WO1999050425A2 (en) * | 1998-03-30 | 1999-10-07 | Baylor College Of Medicine | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| ATE359267T1 (de) * | 1998-06-03 | 2007-05-15 | Guilford Pharm Inc | Azaheterozyklischederivate zur behandlung von haarausfall und neurologischer krankheiten |
| CN101245043B (zh) * | 1998-06-03 | 2013-02-13 | Gpinil控股公司 | N-杂环化合物的羧酸和羧酸电子等排物 |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
| CA2343917A1 (en) | 1998-10-19 | 2000-04-27 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| AU3770800A (en) | 1999-03-26 | 2000-10-16 | Amgen, Inc. | Beta secretase genes and polypeptides |
| CN1382140A (zh) | 1999-07-09 | 2002-11-27 | 奥索-麦克尼尔药品公司 | 具有神经营养活性的吡咯烷和哌啶、以及含有它们的相关组合物 |
| AU6611800A (en) * | 1999-08-05 | 2001-03-05 | Procter & Gamble Company, The | Method of treating hair loss using multivalent ketoamides and amides |
| WO2001010838A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent compounds |
| WO2001010837A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent sulfonamides |
| US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US6900043B1 (en) | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
| EP1125925A1 (de) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amin-Derivate zur Behandlung von Apoptosis |
| TWI322154B (en) | 2000-03-16 | 2010-03-21 | Amgen Inc | Il-17 receptor like molecules and uses thereof |
| US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| MXPA02012747A (es) | 2000-06-28 | 2003-09-25 | Amgen Inc | Moleculas del receptor de linfopoietina estromica timica y sus usos. |
| US7662924B2 (en) | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
| ES2249986B1 (es) * | 2004-07-02 | 2007-02-01 | Universidad Complutense De Madrid | Sintesis de derivados fluorescentes de tacrolimus (fk506) y su uso en la caracterizacion de la interaccion de fk506 con proteinas de union a fk506. |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| EA024751B8 (ru) | 2008-06-04 | 2020-01-31 | Амген Инк. | Мутанты fgf21 и их применение |
| EP2358749B1 (de) | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21-mutanten und ihre verwendungen |
| SMT202400036T1 (it) | 2009-05-05 | 2024-03-13 | Amgen Inc | Mutanti fgf21 e loro utilizzi |
| US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| SG10201908848RA (en) | 2010-03-29 | 2019-10-30 | Univ Pennsylvania | Pharmacologically induced transgene ablation system |
| US9517264B2 (en) | 2010-04-15 | 2016-12-13 | Amgen Inc. | Human FGF receptor and β-Klotho binding proteins |
| EP2699688A1 (de) | 2011-04-20 | 2014-02-26 | The Trustees Of The University Of Pennsylvania | Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern |
| WO2013186264A1 (en) | 2012-06-12 | 2013-12-19 | Universitätsspital Basel | Immortalized mesenchymal stem cells that can be killed through an inducible apoptosis system |
| US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| CN103242218B (zh) * | 2013-05-24 | 2015-04-15 | 深圳市天和医药科技开发有限公司 | N-取代哌可酸衍生物及其制备方法与应用 |
| SI3888674T1 (sl) | 2014-04-07 | 2024-08-30 | Novartis Ag | Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19 |
| CA2963935A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| IL253149B2 (en) | 2014-12-29 | 2023-11-01 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| IL303972A (en) | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US11535665B2 (en) | 2015-05-13 | 2022-12-27 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| AU2016380262B2 (en) | 2015-12-28 | 2023-02-09 | Novartis Ag | Methods of making chimeric antigen receptor -expressing cells |
| EP3464375A2 (de) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutische schemata für chimäre antigenrezeptor(car)-exprimierende zellen |
| MY200337A (en) | 2016-10-07 | 2023-12-20 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain |
| JP2019535281A (ja) | 2016-11-21 | 2019-12-12 | トリビオティカ・エルエルシー | 鋳型化アセンブリ反応による、タンパク質の指向性折り畳みアセンブリまたは二量体化のための方法 |
| EP3541952A4 (de) | 2016-11-21 | 2020-06-24 | Tribiotica Llc | Verfahren zur verhinderung der titrierung von bimolekularen template-reaktionen durch strukturell festgelegte differentielle hybridisierungen |
| SI3589730T1 (sl) | 2017-02-28 | 2024-04-30 | The Trustees Of The University Of Pennsylvania | Adeno-povezan virus (AAV) clade F vektor in njihova uporaba |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| US10786568B2 (en) | 2017-02-28 | 2020-09-29 | The Trustees Of The University Of Pennsylvania | AAV mediated influenza vaccines |
| CA3063719A1 (en) | 2017-05-19 | 2018-11-22 | The Regents Of The University Of California | Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies |
| RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
| EP3788369A1 (de) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses |
| EP3801769A1 (de) | 2018-05-25 | 2021-04-14 | Novartis AG | Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car) |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3844267B1 (de) | 2018-08-31 | 2025-06-25 | Novartis AG | Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors |
| EP3844265A2 (de) | 2018-08-31 | 2021-07-07 | Novartis AG | Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| CN109734655B (zh) * | 2019-03-11 | 2020-06-02 | 都创(上海)医药科技有限公司 | 一种fkbp配体的同型二聚体合成工艺 |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP4104187A1 (de) | 2020-02-14 | 2022-12-21 | Novartis AG | Verfahren zur vorhersage des ansprechens auf eine chimäre antigen-rezeptor-therapie |
| KR20220146530A (ko) | 2020-02-27 | 2022-11-01 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포의 제조 방법 |
| MX2023005609A (es) | 2020-11-13 | 2023-05-29 | Novartis Ag | Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car). |
| EP4256065A2 (de) | 2020-12-01 | 2023-10-11 | The Trustees of The University of Pennsylvania | Neue zusammensetzungen mit gewebespezifischen zielmotiven und zusammensetzungen damit |
| EP4334334A1 (de) | 2021-04-23 | 2024-03-13 | The Trustees of The University of Pennsylvania | Neue zusammensetzungen mit hirnspezifischen zielmotiven und zusammensetzungen damit |
| US20240384298A1 (en) | 2021-10-02 | 2024-11-21 | The Trustees Of The University Of Pennsylvania | Novel aav capsids and compositions containing same |
| KR20240137067A (ko) | 2022-01-25 | 2024-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 개선된 심장 형질도입 및 간의 탈표적화를 위한 aav 캡시드 |
| JP2025531220A (ja) | 2022-09-15 | 2025-09-19 | ノバルティス アーゲー | キメラ抗原受容体療法を使用した自己免疫障害の治療 |
| KR20250135916A (ko) | 2022-12-17 | 2025-09-15 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 심장 및 골격근 특이적 표적화 모티프를 갖는 재조합 aav 돌연변이체 벡터 및 이를 포함하는 조성물 |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| TW202516019A (zh) | 2023-06-29 | 2025-04-16 | 賓州大學委員會 | 具中樞神經系統靶向模體的突變aav及含有其之組成物 |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120727A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5162333A (en) * | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| FI953812A0 (fi) * | 1993-02-12 | 1995-08-11 | Univ Leland Stanford Junior | Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja |
| US5798355A (en) * | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| AU3367995A (en) * | 1994-08-18 | 1996-03-14 | Ariad Pharmaceuticals, Inc. | New multimerizing agents |
| CA2244363C (en) * | 1996-02-28 | 2006-11-14 | Ariad Gene Therapeutics, Inc. | Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains |
-
1997
- 1997-02-28 CA CA002244363A patent/CA2244363C/en not_active Expired - Lifetime
- 1997-02-28 WO PCT/US1997/003137 patent/WO1997031898A1/en not_active Ceased
- 1997-02-28 WO PCT/US1997/003157 patent/WO1997031899A1/en not_active Ceased
- 1997-02-28 EP EP97907937A patent/EP0888303B1/de not_active Expired - Lifetime
- 1997-02-28 DE DE69739853T patent/DE69739853D1/de not_active Expired - Lifetime
- 1997-02-28 AU AU19809/97A patent/AU731826B2/en not_active Expired
- 1997-02-28 AU AU21927/97A patent/AU2192797A/en not_active Abandoned
- 1997-02-28 AT AT97907937T patent/ATE465149T1/de not_active IP Right Cessation
- 1997-02-28 JP JP53113997A patent/JP4936345B2/ja not_active Expired - Lifetime
-
2012
- 2012-01-10 JP JP2012002326A patent/JP2012131794A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997031898A1 (en) | 1997-09-04 |
| WO1997031899A1 (en) | 1997-09-04 |
| CA2244363C (en) | 2006-11-14 |
| AU2192797A (en) | 1997-09-16 |
| CA2244363A1 (en) | 1997-09-04 |
| AU1980997A (en) | 1997-09-16 |
| AU731826B2 (en) | 2001-04-05 |
| EP0888303A1 (de) | 1999-01-07 |
| JP2012131794A (ja) | 2012-07-12 |
| EP0888303B1 (de) | 2010-04-21 |
| JP2000505475A (ja) | 2000-05-09 |
| JP4936345B2 (ja) | 2012-05-23 |
| DE69739853D1 (de) | 2010-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE465149T1 (de) | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen | |
| EP0776327A4 (de) | Neues multimerisierendes reagenz | |
| MY118498A (en) | Lactam derivatives | |
| BR9510420A (pt) | Azetidin-2-onas substituìdas para o tratamento de aterosclerose | |
| ATE218859T1 (de) | Liganden des neuropeptids y | |
| DK0778277T3 (da) | Substituerede heterocycliske derivater som CRF antagonister | |
| ATE355841T1 (de) | Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer | |
| DE69331774D1 (de) | 7-Substituierte-8-substituierte-9-substituierte Amino-7-Demethyl-6-Deoxy-Tetracycline als antibiotische Mittel | |
| ATE114114T1 (de) | Verwendung von benzimidazol-derivaten als antibakterielle mittel. | |
| DE68925155D1 (de) | Verwendung von Halogenkohlenwasserstofflösungsmittel als Reinigungsmittel | |
| PL341239A1 (en) | Dihydrobenzofuranes | |
| BR0113583A (pt) | 2-guanidino-4-arilquinazolinas | |
| ATE326512T1 (de) | Mischungen von beta-hydroxyalkylamiden und ihre verwendung als vernetzungsmittel bei der herstellung von pulverlacken | |
| ATE167664T1 (de) | Verwendung von aminen in ölzusammensetzungen | |
| DE69017627D1 (de) | Isochinolinderivate und ihre Salze als Proteasehemmer. | |
| DE69526097D1 (de) | Bicyclische carboxamide als 5-ht1a rezeptoren liganden | |
| TW340788B (en) | Ester compounds and household insects-controlling agents containing the same as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |